Form 4: Elevation Oncology CEO Joseph Ferra Jr. Reports Stock Transactions
SEC Form 4 Filing
CEO Joseph Ferra Jr. reports stock transactions involving common stock and restricted stock units.
Summary
- On September 16, 2024, Joseph Ferra Jr., CEO of Elevation Oncology, Inc., reported transactions involving the company's common stock and restricted stock units (RSUs).
- Ferra acquired 12,562 shares of common stock through the vesting of RSUs.
- He also disposed of 4,628 shares to cover tax obligations at a price of $0.61 per share.
- Following these transactions, Ferra directly owns 101,548 shares of common stock and 37,685 RSUs.
Sentiment
Score: 5
Explanation: This is a neutral report of stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's performance.
Industry Context
This is a standard SEC Form 4 filing, which is a routine disclosure of stock transactions by company insiders. It provides transparency into the trading activities of key personnel and their holdings in the company.
Stakeholder Impact
- The transactions could have a minor impact on shareholders due to the change in ownership, but the amounts are relatively small.
Key Dates
| Date | Description |
|---|---|
| June 16, 2022 | 25% of the RSUs vested. |
| September 16, 2024 | Date of the reported transactions: acquisition of 12,562 shares via RSU vesting and disposal of 4,628 shares for tax obligations. |
| September 18, 2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.